Background: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP). The role of radiotherapy (RT) after complete response (CR) to RCHOP in patients with DLBCL remains unclear. This systematic review with a meta-analysis is an attempt to evaluate this role. Methods: Studies that evaluated RT versus no-RT after CR to RCHOP for DLBCL patients were searched in databases. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were calculated using a random-effects model. Results: A total of 4 qualified retrospective studies (633 patients) were included in this review. The results suggested that RT improved overall survival (OS; HR 0.33, 95% CI 0.14-0.77) and progression-free/event-free survival (PFS/EFS; HR 0.24, 95% CI 0.11-0.50) in all patients compared with no-RT. In a subgroup analysis of patients with stage III-IV DLBCL, RT improved PFS/EFS (HR 0.19, 95% CI 0.07-0.51) and local control (HR 0.12, 95% CI 0.03-0.44), with a trend of improving OS (HR 0.35, 95% CI 0.12-1.05). Conclusion: Consolidation RT could significantly improve outcomes of DLBCL patients who achieved a CR to RCHOP. However, the significance of these results was limited by these retrospective data. Further investigation of the role of consolidation RT in the rituximab era is needed.

Journal Section:
Editor's choice
Keywords:
Diffuse large B-cell lymphoma, Radiation, Rituximab, Complete response
1.
Clarke C: Non-Hodgkin lymphoma. www.seer.cancer.gov/publications/survival/surv_ nonhodgkin, National Cancer Institute, 2011.
https://doi.org/10.1016/S0140-6736(12)60605-9
2.
Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:3032-3038.
[PubMed]
https://doi.org/10.1200/JCO.2004.06.088
3.
Aviles A, Fernandezb R, Perez F, Nambo MJ, Neri N, Talavera A, Castaneda C, Gonzalez M, Cleto S: Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 2004;45:1385-1389.
[PubMed]
https://doi.org/10.1080/10428190410001667712
4.
Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz-Maqueo JC: Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 1994;30:799-803.
[PubMed]
https://doi.org/10.1016/0360-3016(94)90352-2
5.
Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, Ferme C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787-792.
[PubMed]
https://doi.org/10.1200/JCO.2006.07.0722
6.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
[PubMed]
https://doi.org/10.1200/JCO.2005.09.131
7.
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol 2006;7:379-391.
[PubMed]
https://doi.org/10.1016/S1470-2045(06)70664-7
8.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045.
[PubMed]
https://doi.org/10.1182/blood-2010-03-276246
9.
Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) group. Lancet Oncol 2011;12:1013-1022.
[PubMed]
https://doi.org/10.1016/S1470-2045(11)70235-2
10.
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics 2002. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
11.
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
[PubMed]
https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
12.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[PubMed]
https://doi.org/10.1186/1745-6215-8-16
13.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled clinical trials 1986;7:177-188.
[PubMed]
https://doi.org/10.1016/0197-2456(86)90046-2
14.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
[PubMed]
https://doi.org/10.1136/bmj.327.7414.557
15.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
[PubMed]
https://doi.org/10.1136/bmj.315.7109.629
16.
Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170-4176.
[PubMed]
https://doi.org/10.1200/JCO.2009.27.3441
17.
Marcheselli L, Marcheselli R, Bari A, Liardo EV, Morabito F, Baldini L, Brugiatelli M, Merli F, Di Renzo N, Sacchi S: Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011;52:1867-1872.
[PubMed]
https://doi.org/10.3109/10428194.2011.585526
18.
Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR: Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 2012;84:762-767.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2011.12.067
19.
Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK: Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:569-577.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2013.02.007
20.
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26.
[PubMed]
https://doi.org/10.1056/NEJM199807023390104
21.
Miller TP, Leblanc M, Spier CM, Chase E, Fischer RI: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98:742a-743a.
22.
Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205.
[PubMed]
https://doi.org/10.1056/NEJMoa042040
23.
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
[PubMed]
24.
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP: Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. J Clin Oncol 2008;26:2258-2263.
[PubMed]
https://doi.org/10.1200/JCO.2007.13.6929
25.
Pfreundschuh M, Ziepert M, Reiser M, Poeschel V, Wilhelm S, Gaska T, Heike M, Schmitz N, Ruebe C, Loeffler M, Schubert J: The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL. 50th Annual Meeting of the American Society of Hematology, Moscone Center, San Francisco, 2008.
26.
Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 2014;32:1112-1118.
[PubMed]
https://doi.org/10.1200/JCO.2013.51.4505
27.
Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A: Modern radiation therapy for nodal non-Hodgkin lymphoma - target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2014;89:49-58.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2014.01.006
28.
Shi Z, Esiashvili N, Flowers C, Das S, Khan MK: Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54:2122-2130.
[PubMed]
https://doi.org/10.3109/10428194.2013.779687
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.